PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
Travel sourcing and consultancy group Partnership Travel Consulting has named former Corporate Travel Management executive Maureen Brady as its chief commercial officer, a new position for the group.
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
GlobalData on MSN13h
FDA grants accelerated approval for PTC’s AADC deficiency gene therapyThis therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...
This system will become Sara and it is expected to enter the Gulf of Mexico next week. Could it impact Florida? How?
This system will become Sara and it is expected to enter the Gulf of Mexico next week. Could it impact Florida? How?
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
It is too soon to discuss any impacts that Florida could experience from Potential Tropical Cyclone 19 / Sara.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback